Last week during the second session of our P&MA strategy course (a collaboration between Windrose and Cambridge University), our guest Andrew Walker produced this nugget:

“Uncertainty has been weaponised by payers”

A global pharmaceutical company was preparing to file a reimbursement dossier for the prevention of migraine in Canada and Europe.

Mark Kohler promoted to Principal and William Noumba Um to Senior Analyst at Windrose Consulting Group.

On Friday, April 22nd, 2022, Biogen announced that it had withdrawn the marketing application in the EU for aducanumab (Aduhelm), its monoclonal antibody that targets aggregated forms of amyloid beta found in the brains of Alzheimer’s patients.

Our client had recently received EMA approval for a novel androgen receptor inhibitor, indicated within several solid tumors.

We are pleased to release the second edition of our Windrose Consulting Group: Global News Roundup for Q1 2022.

Our client had a Phase III biosimilar for the treatment of febrile neutropenia in the pipeline, with an estimated 5-years to launch

Our client had a late-stage vaccine candidate targeting older adult (OA) respiratory syncytial virus (RSV), and wanted support with its US pricing and access strategy.

The application of biomarkers in therapy areas beyond oncology will likely play an ever-crucial role in developing more targeted therapies in high unmet need indications, while providing payers with new attributes by which to assess a new treatment’s value.

A global pharmaceutical company had a Phase II/III enzyme replacement therapy in development for a rare genetic disorder that targeted symptoms not addressed by current standard of care.

We are delighted to welcome Mattia Belloni as a Senior Consultant at Windrose.

Windrose conducted a pricing, market access and evidence gap assessment across US, EU4 and UK for two novel agents in a muscle weakness disorder

On the 9th March Windrose ran a 1-day workshop for the masters students on the Cambridge University MPhil in Therapeutic Sciences course. The content included ‘Why it’s important to get your P&MA right’, delved into stakeholder decision analysis, the various payer systems & market archetypes, how to optimise the global strategy and communicate value.

This article will describe the cost-containment measures introduced by the new government and how they influence drugs’ pricing and market access potential.

We are pleased to announce that Agatha Cimbalova and Anjalina Mitra have been promoted to Senior Analysts. This promotion is a recognition of Agatha and Anjie’s dedication, hard work, and great progression that has been observed over their time working at Windrose.

Congratulations!

Our client was evaluating an orphan indication for Product X, which is currently indicated for another orphan indication in Europe, Japan, and Latin America.

Download the report to find out about the German pharmaceutical pricing & reimbursement process, including, Payer Evaluation, Price setting, Reimbursement and Cost containment.

Download the report to find out how pricing and reimbursement decisions are made in The Netherlands, including, Payer Evaluation, Price setting and reimbursement

Download the report to find out how pricing and reimbursement decisions are made in Italy, including, Payer Evaluation, Price setting and reimbursement

Download the report to find out how pricing and reimbursement decisions are made in Spain, including, Payer Evaluation, Price setting and reimbursement